PBYI

Puma Biotechnology Inc

4.06 USD

Last updated Dec 10, 00:31 UTC

Yesterday HIGH

$4.3

Yesterday LOW

$4.11

52w HIGH

$5.16

52w LOW

$2.13

EPS

0.17

PE

23.88

Next Earnings

Feb 29, 2024

Overview News Government Trades

Puma Biotechnology Inc stock is up 22.66% since 30 days ago. The next earnings date is Feb 29, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 25% of the previous 11 December’s closed higher than November.

Puma Biotechnology, Inc. focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd.

Stock Exchange

NASDAQ

Sector

Manufacturing

Industry

Pharmaceutical Products

Headquarters

Los Angeles, United States Of America

Website

pumabiotechnology.com

Benzinga Insights

Thu May 4, 2023

Earnings Scheduled For May 4, 2023

Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is estimated to report quarterly loss at $1.83 per share on revenue of $104.21 million.
Happy Mohamed

Tue Apr 18, 2023

Puma Biotechnology Awarded $8,562,530 Contract From Department Of Veterans Affairs For Pharmaceutical Preparation Manufacturing

https://sam.gov/opp/9a02060ad5ea45eebfc0e83765eab3f4/view
Lisa Levin

Thu Mar 30, 2023

Why Bed Bath & Beyond Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Gainers SCYNEXIS, Inc. (NASDAQ: SCYX) shares climbed 68% to $2.8184 after the company announced an exclusive license agreement with GSK for Brexafemme, in which the company will receive an upfront payment of $90 million.
Happy Mohamed

Tue Mar 14, 2023

Puma Biotechnology Announces Publication Of Phase II Clinical Trial Of Alisertib In JAMA Oncology

Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that the results of the Phase II TBCRC041 randomized clinical trial of alisertib alone or in combination with fulvestrant in patients with
richadhand@benzinga.com

Mon Mar 6, 2023

HC Wainwright & Co. Reiterates Buy on Puma Biotechnology, Maintains $8 Price Target

HC Wainwright & Co. analyst Edward White reiterates Puma Biotechnology (NASDAQ:PBYI) with a Buy and maintains $8 price target.
Lisa Levin

Fri Mar 3, 2023

Why Puma Biotechnology Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Friday's Mid-Day Session

Gainers ObsEva SA (NASDAQ: OBSV) surged 86.6% to $0.1978 after dropping over 12% on Thursday. ObsEva recently announced strategic reorganization to consolidate operations in Switzerland.
Michael Horton

Thu Mar 2, 2023

Puma Biotechnology Sees Q1 Net Product Revenue $43M-$46M; Sees FY23 Net Product Revenue $205M-$210M
Michael Horton

Thu Mar 2, 2023

Puma Biotechnology Q4 Adj. EPS $(0.07) Misses $0.01 Estimate, Sales $65.70M Beat $57.06M Estimate

Puma Biotechnology (NASDAQ:PBYI) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $0.01 by 800 percent. This is a 133.33 percent decrease over earnings of $0.21 per share from
Benzinga Insights

Thu Mar 2, 2023

Earnings Scheduled For March 2, 2023

Companies Reporting Before The Bell • argenx (NASDAQ:ARGX) is expected to report quarterly loss at $3.03 per share on revenue of $176.89 million.
Happy Mohamed

Wed Feb 1, 2023

Puma Biotechnology's NERLYNX Included In NCCN Clinical Practice Guidelines For The Treatment Of Breast Cancer With A HER2 Mutation

Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer were